[ Inglês] Inside the First FDA-Approved CAR-T Cell Therapy

Published on

Topics include: Treatments

The first CAR T-cell therapy to receive FDA approval, CTL019 (Kymriah) was recently approved for children and young adults with B-cell acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice. Expert Dr. Michael Deinginger joins Patient Power Founder Andrew Schorr to explain CAR T-cell therapy, an approach that uses the body’s own system to fight the disease. Find out why Dr. Deininger calls this approval “revolutionary.”

View more programs featuring and

Related Programs

CAR T-Cell Therapy: An Overview

What is a CAR and what role does CAR T-cell therapy play in targeted therapy? Experts Drs. Nicole Lamanna and Michael Keating explain.


How Does CAR T-Cell Immunotherapy Work?

For several years, researchers have been excited about CAR T-cell immunotherapy. But what is it? Dr. David Maloney explains.


Junte-se a nossa comunidade Cadastre-se para Eventos Leia nosso último blog

Page last updated on September 9, 2019